Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) were down 11% on Wednesday after skyrocketing 56.9% on Tuesday on COVID-19-related news.
What Happened
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
On Monday, Altru Institute’s Altru Global Virus Project published a report on Sonnet suggesting the company’s technology may be valuable in combating COVID-19.
Sonnet’s core technology, Fully Human Albumin Binding, is a delivery mechanism designed for cancer that can also be used for viruses.
“They have invented and developed an ingenious approach that converts endogenous albumin into a drug-loaded and/or immune stimulatory Trojan Horse that is taken up by unknowing cancer cells, leading to their destruction,” Tom Malcom, PhD, CEO of biotech start-up Iron Hills Bioengineering, said in a press release.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
Why It’s Important
Any company developing COVID-19 solutions, from vaccines to treatments to improved testing and tracking methods, stands to make a fortune. With billions of dollars on the line, it’s understandable why the share price of a $65 million company like Sonnet would jump on the news.
However, given there are thousands of companies with nearly unlimited resources all looking for the best treatment for the coronavirus, reality seems to be setting in a bit for Sonnet investors. After initially spiking from under $5 to above $14 on Tuesday morning, Sonnet has been drifting lower ever since.
Benzinga’s Take
Following a merger with Chanticleer Holdings and a 26-to-1 reverse stock split that took place on April 2, Bonnet currently has a minuscule float of only 1.5 million shares, according to Yahoo. With a float that tiny, all it takes is a relatively small catalyst such as this week’s news to trigger enough buying volume to really move the stock.
Do you agree with this take? Email feedback@benzinga.com with your thoughts.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.